- Home
- ENX vs STTK Comparison
ENX vs STTK Comparison
Compare ENX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- STTK
- Stock Information
- Founded
- ENX 2002
- STTK 2016
- Country
- ENX United States
- STTK United States
- Employees
- ENX N/A
- STTK N/A
- Industry
- ENX Finance/Investors Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ENX Finance
- STTK Health Care
- Exchange
- ENX Nasdaq
- STTK Nasdaq
- Market Cap
- ENX 175.5M
- STTK 56.8M
- IPO Year
- ENX N/A
- STTK 2020
- Fundamental
- Price
- ENX $9.48
- STTK $1.12
- Analyst Decision
- ENX
- STTK Hold
- Analyst Count
- ENX 0
- STTK 3
- Target Price
- ENX N/A
- STTK $2.00
- AVG Volume (30 Days)
- ENX 25.4K
- STTK 182.2K
- Earning Date
- ENX 01-01-0001
- STTK 02-27-2025
- Dividend Yield
- ENX 3.94%
- STTK N/A
- EPS Growth
- ENX N/A
- STTK N/A
- EPS
- ENX 0.16
- STTK N/A
- Revenue
- ENX N/A
- STTK $6,435,000.00
- Revenue This Year
- ENX N/A
- STTK $313.04
- Revenue Next Year
- ENX N/A
- STTK N/A
- P/E Ratio
- ENX $61.00
- STTK N/A
- Revenue Growth
- ENX N/A
- STTK 382.75
- 52 Week Low
- ENX $7.84
- STTK $0.94
- 52 Week High
- ENX $10.07
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- ENX 41.09
- STTK 43.75
- Support Level
- ENX $9.42
- STTK $1.13
- Resistance Level
- ENX $9.89
- STTK $1.39
- Average True Range (ATR)
- ENX 0.12
- STTK 0.11
- MACD
- ENX -0.01
- STTK 0.00
- Stochastic Oscillator
- ENX 29.35
- STTK 18.18
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.